Safety and tolerance confirmed
[by Yu, Suin] Contera Pharma, the Danish subsidiary of Bukwang Pharmaceutical, announced on September 17 that it has reported positive top-line results from a Phase 1b clinical trial of CP-012 (development code), a morning akinesia in Parkinson's disease treatment candidate.
Contera Pharma reported top-line findings from a Phase 1b pharmacoscintigraphic study of 바카라 카지노012, an investigational therapy designed to alleviate Parkinson’s disease-related motor complications, specifically nocturnal immobility and morning akinesia. Pharmacoscintigraphic studies employ radioactive isotopes to visualize and evaluate a drug’s movement, location, and release profile within the body.
The exploratory pharmacoscintigraphic study enrolled up to 15 patients with Parkinson's disease and was designed as a single-center, open-label, crossover trial. Its primary objectives were to evaluate the release kinetics of the novel delayed-release 바카라 카지노012 formulation, specifically when and where levodopa and carbidopa are released in the body, and to assess their absorption. In addition, the study analyzed correlations between release timing and anatomical release location as determined through radiological scintigraphy imaging.
바카라 카지노012 is a delayed-release levodopa formulation designed for evening administration, with therapeutic effects the following morning. The clinical trial demonstrated its potential to mitigate morning motor symptoms. Levodopa, which is metabolized to dopamine in the brain, remains the standard of care for Parkinson's disease by addressing dopamine deficiency and alleviating motor dysfunction.
The study was conducted in collaboration with BDD Pharma at its clinical site in Scotland. “In this Phase 1b trial, 바카라 카지노012 demonstrated safety and tolerability in patients with Parkinson’s disease,” said Anne Birk Østerskov, Chief Medical Officer at Contera Pharma. “What is particularly important is that pharmacokinetic and scintigraphy data confirmed 바카라 카지노012’s ability to delay the release of levodopa by several hours, enabling therapeutic activity during the early morning hours when symptoms are most severe.”
“These encouraging results provide a strong rationale for the continued clinical development of 바카라 카지노012,” she added. “We are now one step closer to delivering a much-needed new treatment option for patients with Parkinson’s disease.”
“These Phase 1b clinical trial results provide clinical evidence that the unique release profile, designed to gradually deliver the drug into the body, functions as intended in patients with Parkinson's disease,” expressed Thomas Sager, CEO of Contera Pharma. “These findings bring us closer to our goal of improving the quality of life for Parkinson's patients and are significant in that they provide the data necessary to advance 바카라 카지노012 to the next phase of clinical development.”
“Morning akinesia, a Parkinson's symptom characterized by stiffness and difficulty initiating movement upon waking, affects an estimated 50-75% of patients. Sales of Parkinson's disease therapies across the five major markets, including the U.S. and UK, are projected to increase from USD 3.4 billion in 2023 to approximately USD 7 billion in 2033, underscoring the clear need for a treatment targeting morning akinesia,” said Lee Jae-young, CEO of Bukwang 바카라 카지노ceutical. "According to a report commissioned from an external organization in the first half of 2024, the potential peak annual sales of morning akinesia treatments in eight major countries are estimated at around KRW 1.3 trillion (approximately USD 940.2 million)."
"The successful outcome of this clinical trial offers hope that we may improve the quality of life for patients suffering from morning akinesia, a condition for which effective treatments are currently lacking. I wish to acknowledge the dedication of the Contera Pharma research team in advancing a new therapy for Parkinson's disease, despite the clinical failure of 'JM-010,' a treatment for Parkinson's-related dyskinesia, in May of last year. Bukwang Pharmaceutical and Contera Pharma will now determine the best path forward to ensure the ultimate success of 바카라 카지노012 and advance its development in earnest," Lee further added.